SCHEMBL2278460

SCHEMBL2278460

O=C(Nc1cc(/C=C/c2cccc(O)c2)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
PKM P14618 2/20 0.56
MAPT P10636 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
GRIK1 P39086 1/20 0.55
AKR1C4 P17516 4/20 0.54
AKR1C3 P42330 4/20 0.54
AKR1C2 P52895 4/20 0.54
AKR1C1 Q04828 4/20 0.54
SNCA P37840 3/20 0.50
KDM1A O60341 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
TTR P02766 2/20 0.49
ALDH1A1 P00352 1/20 0.48
ABL1 P00519 1/20 0.48
TSHR P16473 1/20 0.48
RIN1 Q13671 1/20 0.48
LTC4S Q16873 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2278462 1.00 MEN1 (0.56) MEN1KMT2APKMMAPTTDP1
SCHEMBL2276651 0.91 PKM (0.62) MEN1KMT2APKMMAPTTDP1
SCHEMBL2276655 0.91 PKM (0.62) MEN1KMT2APKMMAPTTDP1
SCHEMBL2270237 0.90 KMT2A (0.57) MEN1KMT2APKMMAPTTDP1
SCHEMBL2270230 0.90 KMT2A (0.57) MEN1KMT2APKMMAPTTDP1
SCHEMBL2276459 0.86 GRIK1 (0.57) MEN1KMT2APKMMAPTTDP1
SCHEMBL2276466 0.86 GRIK1 (0.57) MEN1KMT2APKMMAPTTDP1
SCHEMBL2271828 0.85 SNCA (0.61) MEN1KMT2APKMMAPTTDP1
SCHEMBL2271821 0.85 SNCA (0.61) MEN1KMT2APKMMAPTTDP1
SCHEMBL2270271 0.84 PKM (0.54) MEN1KMT2APKMMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 MEN1 3105/4885KMT2A 1669/4885PKM 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.